SHLP-2 vs Humanin

Overview

SHLP-2 (Small Humanin-Like Peptide 2) and Humanin are closely related mitochondria-derived peptides (MDPs), both encoded within the 16S rRNA region of mitochondrial DNA. SHLP-2 was discovered during the search for humanin-related peptides and appears to have distinct but complementary functions. Both are being studied for their roles in aging, metabolism, and cellular protection.

This comparison is relevant for researchers interested in the emerging MDP family and their potential applications in longevity research.

Key Facts

Aspect	SHLP-2	Humanin
Full Name	Small Humanin-Like Peptide 2	Humanin
Discovery	2016 (Cobb/Cohen)	2001 (Hashimoto)
Structure	26 amino acids	24 amino acids
mtDNA Location	16S rRNA region	16S rRNA region
Relationship	SHLP family member	First MDP discovered
FDA Status	Not approved	Not approved

Genomic Relationship

Aspect	SHLP-2	Humanin
mtDNA Region	16S rRNA	16S rRNA
Reading Frame	Distinct from humanin	Original ORF
Discovery Context	Humanin-related search	Alzheimer’s screen
Family	SHLP family (1-6)	Founding MDP

SHLP Family Context

SHLP-2 is part of a family of six SHLPs (Small Humanin-Like Peptides) discovered when researchers searched the 16S rRNA region for additional bioactive peptides after humanin’s discovery. Each SHLP has distinct properties, with SHLP-2 showing particularly interesting cytoprotective and metabolic effects.

Mechanism Comparison

Aspect	SHLP-2	Humanin
Primary Action	Mitochondrial function	Anti-apoptotic
Receptor	Under investigation	FPRL1/2 receptors
Cytoprotection	Yes	Yes (primary)
Metabolic Effects	Yes	Yes (secondary)

SHLP-2 Proposed Mechanisms

1. Mitochondrial Enhancement

   • Improved mitochondrial function
   • ATP production support
   • Mitochondrial biogenesis

2. Cytoprotective Effects

   • Cell survival signaling
   • Stress resistance
   • Apoptosis reduction

3. Metabolic Regulation

   • Insulin sensitivity effects
   • Glucose metabolism
   • Metabolic homeostasis

Humanin Established Mechanisms

1. Receptor Signaling

   • FPRL1/2 receptor binding
   • ERK1/2 and STAT3 activation
   • Anti-apoptotic cascades

2. BAX Inhibition

   • Direct binding to pro-apoptotic BAX
   • Prevents mitochondrial permeabilization
   • Blocks cell death cascade

3. IGF Pathway Modulation

   • IGFBP-3 binding
   • Modulates growth factor signaling
   • Metabolic effects

Evidence Quality

Factor	SHLP-2	Humanin
Human Studies	~5 (biomarker)	10+ (biomarker)
Animal Studies	~10	40+
Cell Studies	Multiple	Extensive
Clinical Trials	None	None
Overall Evidence	Very Low	Moderate

Research Volume Comparison

Aspect	SHLP-2	Humanin
Discovery Date	2016	2001
Research Years	~10	~25
Publications	~30	~500+
Research Groups	Primarily Cohen lab	Many worldwide
Mechanism Clarity	Emerging	Well-characterized

Human Biomarker Studies

SHLP-2 in Humans

Finding	Study Type	Implication
Declines with age	Observational	Aging marker
Lower in prostate cancer	Case-control	Disease association
Correlates with metabolic health	Observational	Metabolic link

Humanin in Humans

Finding	Study Type	Implication
Declines with age	Multiple studies	Aging marker
Lower in Alzheimer’s	Observational	Cognitive link
Inverse to insulin resistance	Observational	Metabolic link
Higher in centenarians’ children	Genetic study	Longevity association

Preclinical Research

SHLP-2 Studies

Finding	Model	Source
Cell survival enhancement	Cell culture	Cobb 2016
Mitochondrial function support	Cellular	Cohen lab
Insulin signaling effects	Cellular	Early studies

Humanin Studies

Finding	Model	Source
Reduced amyloid pathology	APP mice	Tajima 2005
Cardioprotection	I/R models	Multiple
Insulin sensitivity	Diabetic mice	Muzumdar 2009
Broad cytoprotection	Multiple models	Many labs

Disease Research Focus

SHLP-2 Applications

Area	Evidence Level	Notes
Aging/longevity	Very low	Biomarker data
Cancer biology	Very low	Prostate cancer studies
Metabolic health	Very low	Early research
Mitochondrial disease	Theoretical	Mechanism-based

Humanin Applications

Area	Evidence Level	Notes
Neurodegeneration	Low-Moderate	Extensive preclinical
Cardiovascular	Low	Ischemia models
Metabolic disease	Low	Diabetes models
Aging	Low	Biomarker studies

Administration and Pharmacology

Aspect	SHLP-2	Humanin
Route (research)	Injection	Injection
Bioavailability	Unknown	Being studied
Analogs	None developed	HNG (1000x potent)
Half-life	Unknown	Being studied

Potency and Analogs

SHLP-2

• Native peptide used in research
• No enhanced analogs developed yet
• Structure-activity relationship being studied

Humanin

Analog	Enhancement	Use
HNG (S14G-Humanin)	1000x more potent	Research standard
Colivelin	Combination peptide	Neuroprotection research
Various modifications	Stability improvements	Development

Safety Profile

SHLP-2

Aspect	Status
Human safety data	None
Endogenous peptide	May suggest tolerability
Long-term effects	Unknown
Concerns	Too early to characterize

Humanin

Aspect	Status
Human safety data	None (no trials)
Anti-apoptotic	Theoretical cancer concern
Long-term effects	Unknown
Concerns	Complex mechanism

SHLP Family Context

SHLP	Size	Known Function
SHLP-1	15 AA	Mitochondrial function
SHLP-2	26 AA	Cytoprotection, metabolism
SHLP-3	26 AA	Under study
SHLP-4	26 AA	Under study
SHLP-5	26 AA	Under study
SHLP-6	22 AA	Potential pro-apoptotic

Synergy Potential

Factor	Consideration
Same mtDNA region	May have coordinated roles
Similar functions	Potential redundancy or synergy
Age-related decline	Both decrease together
Combination studies	None conducted

Regulatory Status

Aspect	SHLP-2	Humanin
FDA Status	Not approved	Not approved
Clinical trials	None	None
Research chemical	Limited availability	Available
Pharmaceutical development	Not active	Not active

Summary

Factor	SHLP-2	Humanin
Structure	26 amino acids	24 amino acids
mtDNA Region	16S rRNA	16S rRNA
Discovery	2016	2001
Primary Action	Mitochondrial function	Cytoprotection
Evidence Level	Low	Moderate
Research Volume	Limited	Extensive
Human Trials	None	None
Analog Development	None	HNG available

Key Takeaways

1. Related peptides: Both from 16S rRNA region of mtDNA
2. SHLP-2 is newer: 15 years less research than humanin
3. Different mechanisms: SHLP-2 mitochondrial focus vs humanin anti-apoptotic
4. Humanin has more data: ~500 publications vs ~30 for SHLP-2
5. Both decline with age: Suggests roles in aging process
6. Neither in trials: Despite years of research
7. SHLP family exists: SHLP-2 is one of six related peptides
8. Humanin analogs exist: HNG is 1000x more potent; no SHLP-2 analogs yet

---

This comparison is for educational purposes only. Neither peptide is approved for any clinical use. Both are research compounds with no completed human therapeutic trials.